datopotamab deruxtecan
FDA Grants Accelerated Approval to Datroway for Some Patients With EGFR-Mutated NSCLC
The FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for adults with ...
JUNE 24, 2025
Datopotamab Deruxtecan Shines in Metastatic Breast Cancer
In patients with inoperable or metastatic hormone receptor–positive (HR-positive), HER2-negative breast ...
NOVEMBER 22, 2023
Load more